Mixtard 50 Penfill (Insulin Human)

Insulin human, the active ingredient in Mixtard 50 Penfill, is an insulin presented as a pre‑filled pen for subcutaneous use. It lowers blood glucose by replacing deficient endogenous insulin in individuals with type 1 or type 2 diabetes mellitus and is used under medical supervision to achieve glycaemic control.

GNH USA supplies Mixtard 50 Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory‑aligned distribution, and technical support for diabetes care programs across multiple regions.

Mixtard 50 Penfill contains insulin human, an antidiabetic agent that replaces endogenous insulin to control blood glucose.

- Type 1 diabetes mellitus: provides required insulin to maintain glycaemic control. - Type 2 diabetes mellitus: supplements endogenous insulin to improve glucose regulation. - Pre‑meal hyperglycemia: helps achieve post‑prandial glucose targets when combined with meals. - Basal insulin requirement: delivers basal insulin coverage as part of a basal‑bolus regimen. - Gestational diabetes mellitus: may be used under specialist supervision to control maternal glucose levels.

Adverse reactions may occur with insulin therapy and should be monitored.

Common Side Effects: - Hypoglycemia: symptoms such as sweating, tremor, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with insulin therapy. - Lipodystrophy: localized fat accumulation or loss at injection sites.

Serious or Rare Side Effects: - Severe hypoglycemia: loss of consciousness or seizures requiring emergency care. - Anaphylactic reaction: difficulty breathing, swelling of face or throat. - Insulin antibodies: may cause unpredictable glucose control.

When using Mixtard 50 Penfill, several safety considerations are recommended.

- Hypoglycemia risk: monitor blood glucose regularly and adjust dose as needed. - Dose adjustments: required when changing diet, physical activity, or concomitant medications. - Renal impairment: may need lower dose and close monitoring of glucose. - Pregnancy and lactation: use only if benefits outweigh potential risks to mother and fetus. - Drug interactions: avoid or monitor use with sulfonylureas, beta‑blockers, and other hypoglycemic agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin human can interact with several drug classes, influencing glucose control.

Major Interactions (Avoid): - Sulfonylureas: combined use can cause severe hypoglycemia. - Beta‑blockers: may mask hypoglycemia symptoms, requiring careful monitoring.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin’s glucose‑lowering effect. - Thiazide diuretics: can increase blood glucose levels, necessitating dose review. - Corticosteroids: may raise insulin requirements, requiring dose adjustment.